SANTA ROSA, Calif., Oct. 29, 2014 (GLOBE NEWSWIRE) -- TriVascular Technologies, Inc. (Nasdaq:TRIV), manufacturer of the Ovation Prime® Abdominal Stent Graft System, today announced the Company will be participating in three upcoming investor conferences.
TriVascular management is scheduled to present at the Credit Suisse 2014 Annual Healthcare Conference in Phoenix on November 13, 2014 at 8:00am MT/10:00am ET.
TriVascular management is also scheduled to present at the 2014 Stifel Healthcare Conference in New York City on November 18, 2014 at 4:10pm ET.
TriVascular management will also present at the 2014 Canaccord Medical Technology and Diagnostics Forum in New York City on Thursday November 20, 2014 at 11:00am ET.
Interested individuals can access the live audio webcast for each event on the investor relations section of the Company's website at: http://www.trivascular.com. Each webcast will be available on the Company's website for two weeks following completion of the presentation.
About TriVascular Technologies, Inc. - TriVascular is a medical device company developing and commercializing innovative technologies to significantly advance minimally invasive treatment of abdominal aortic aneurysms. The company manufactures the Ovation Prime Abdominal Stent Graft System, the lowest profile FDA-approved endovascular aortic repair (EVAR) system, which utilizes a novel, polymer-based sealing mechanism. TriVascular is based in Santa Rosa, California.